It’s a bit cryptic …
From the quarterly on the 30th Jan it was said ….
“There were preliminary signs of efficacy from the 14 patients dosed in the Phase 1b trial.”
From today’s Ann …
Of these fourteen patients seven (7) patients remained on trial for >6 months, with two (2)
patients being on trial for more than 10 months.
Six (6) patients have now recorded a partial response as best response, with the remaining
eight (8) recording stable disease.
6 and 8 presumably that’s the 14 patients in question from 1b trail
No mention of any deaths …
These response rates are substantially higher than predicted from historical studies of
gemcitabine and Abraxane treatment alone.
And importantly, … Three (3) patients remain on trial from the Phase 1b cohort.
.
Ann: Update on ACCENT Trial in Pancreatic Cancer, page-7
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
15.0¢ |
Change
0.005(3.45%) |
Mkt cap ! $41.21M | |||
| Open | High | Low | Value | Volume |
| 15.5¢ | 16.0¢ | 15.0¢ | $55.88K | 361.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 94946 | 15.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 16.0¢ | 56159 | 1 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| ATX (ASX) Chart |